Analyst Keeps Quidel (QDEL) At Buy as CDC Sees Uptick in Influenza
Tweet Send to a FriendGet Alerts QDEL Hot Sheet
Price: $23.04 +0.96%
Rating Summary:
4 Buy, 4 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
4 Buy, 4 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade QDEL Now!
The national baseline for Influenza was 2.2 percent last week, according to data from the CDC. This is one of the earliest times the Influenza rate reached this level during the past four flu seasons, noted analyst Jeffrey Frelick of Canaccord Genuity.
"At this time last year, ILI activity was only 1.56% of total outpatient visits. Flu activity did not reach this high a level last season until week 8, topping out at 2.38%," observed Frelick.
Frelick views this data as positive for the launch of Quidel's (QDEL) new Sofia immunoassay platform.
"While QDEL now derives about 28% of its revenue from flu tests (down from 45% in 2008), we think the new Sofia system is positioned to perform well in 2013," concluded the analyst.
Canaccord Genuity has a Buy rating on Quidel Corp. (NASDAQ: QDEL) with a price target of $25.00.
For an analyst ratings summary and ratings history on Quidel Corp. click here. For more ratings news on Quidel Corp. click here.
Shares of Quidel Corp. closed at $17.53 yesterday, with a 52 week range of $14.08-$19.37.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
"At this time last year, ILI activity was only 1.56% of total outpatient visits. Flu activity did not reach this high a level last season until week 8, topping out at 2.38%," observed Frelick.
Frelick views this data as positive for the launch of Quidel's (QDEL) new Sofia immunoassay platform.
"While QDEL now derives about 28% of its revenue from flu tests (down from 45% in 2008), we think the new Sofia system is positioned to perform well in 2013," concluded the analyst.
Canaccord Genuity has a Buy rating on Quidel Corp. (NASDAQ: QDEL) with a price target of $25.00.
For an analyst ratings summary and ratings history on Quidel Corp. click here. For more ratings news on Quidel Corp. click here.
Shares of Quidel Corp. closed at $17.53 yesterday, with a 52 week range of $14.08-$19.37.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
- Deutsche Bank Takes Aegerion (AEGR) Price Target from $52 to $85
- Compass Point Boosts Numbers on RLJ Lodging Trust (RLJ)
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS ViewRelated Entities
Canaccord Genuity
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
